The world is talking about ending AIDS. AVAC’s advocacy is dedicated to realizing that vision. To get there we must:
Yesterday, the US Food and Drug Administration (FDA) announced its approval of Gilead’s drug Descovy (also known as F/TAF) as daily oral PrEP for adults and adolescents, except those who have “receptive vaginal sex.”
Please join AVAC, the Treatment Action Group (TAG), The Well Project and the Women’s Research Initiative (WRI) on Monday, October 7 at 9-10am ET for an Advocates’ Debrief on the Science of Daily F/TAF vs. TDF/FTC as PrEP.
A few important new resources are up on AVAC.org and PrEPWatch.org. Read on for highlights and links.
The World Health Organization (WHO) released updated guidance on “Hormonal Contraceptive Eligibility for Women at High Risk of HIV”. We are gravely concerned that this guidance will be used to justify a “business as usual” approach in which contraceptive procurement, program design, service delivery and counseling approaches go unchanged.
AVAC has an extensive online resource library with hundreds of Reports, Publications, Infographics & more. And it includes powerful search features to find exactly what you’re looking for.
AVAC uses education, policy analysis, advocacy, community mobilization and a network of global collaborations to accelerate ethical development and global delivery of biomedical HIV prevention options. Read more
AVAC advocates for a comprehensive response to the epidemic, involving smart use of every proven HIV prevention option available today and sustained research into many new strategies.